Pure Biologics S.A. (Poland)

Pure Biologics S.A. is a biopharmaceutical company located in Wroclaw, Poland. The company specializes in the discovery and development of biologic drugs and the development of extracorporeal therapies. They focus on the areas of immuno-oncology, autoimmunology, and rare neurological diseases. Pure Biologics conducts research using their own technological platforms for the selection of active particles, such as antibodies and aptamers. They also offer commercial collaboration in various areas, including early-stage development of biologic drugs, antibody and aptamer selection and characterization, as well as protein production, purification, and analysis. Pure Biologics has been operating in the market since 2010 and is one of the largest biotechnology companies in the country, employing approximately 50 people. In 2022, the company established a subsidiary called Doto Medical, focused on accelerating the development and commercialization of their key aptamer project, PB103, in collaboration with the established biomedical company Relitech BV. The project aims to develop a medical device for patients with chronic kidney disease (CKD). Pure Biologics has also entered into a partnership with the renowned transaction advisor Clairfield Partners. Their therapeutic portfolio includes new immuno-oncology therapies and extracorporeal therapies for autoimmune, neurodegenerative, and rare diseases.